Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA marker

• Published in: The Journal of pathology Vol. 247; no. 5; pp. 641 - 649
• Main Authors: Lam, Wai Kei Jacky, Chan, Kwan Chee Allen, Lo, Yuk Ming Dennis
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.04.2019; Wiley Subscription Services, Inc
• Subjects: Biological properties; Biomarkers, Tumor - metabolism; Biopsy; Cancer; circulating tumour DNA (ctDNA); Deoxyribonucleic acid; DNA; DNA, Viral - metabolism; Early Detection of Cancer; Epstein-Barr virus; Herpesvirus 4, Human - genetics; Humans; Invited Review; Invited Reviews; liquid biopsy; massively parallel sequencing; Nasopharyngeal carcinoma; Nasopharyngeal Neoplasms - blood; Nasopharyngeal Neoplasms - diagnosis; Neoplasm Recurrence, Local; Plasma; Prognosis; screening; size‐based diagnostics; Therapeutic applications; Throat cancer; Tumors; nasopharyngeal carcinoma; screening; circulating tumour DNA (ctDNA); liquid biopsy; massively parallel sequencing; size-based diagnostics
• ISSN: 0022-3417; 1096-9896
• DOI: 10.1002/path.5249

Analysis of circulating tumour DNA (ctDNA), as one type of ‘liquid biopsy’, has recently attracted great attention. Researchers are exploring many potential applications of liquid biopsy in many different types of cancer. In particular, it is of biological interest and clinical relevance to study the molecular characteristics of ctDNA. For such purposes, plasma Epstein–Barr virus (EBV) DNA from patients with nasopharyngeal carcinoma (NPC) would provide a good model to understand the biological properties and clinical applications of ctDNA in general. The strong association between EBV and NPC in endemic regions has made plasma EBV DNA a robust biomarker for this cancer. There are many clinical utilities of plasma EBV DNA analysis in NPC diagnostics. Its role in prognostication and surveillance of recurrence is well established. Plasma EBV DNA has also been validated for screening NPC in a recent large‐scale prospective study. Indeed, plasma EBV DNA could be regarded as an archetypal ctDNA marker. In this review, we discuss the biological properties of plasma EBV DNA from NPC samples and also the clinical applications of plasma EBV DNA analysis in the management of NPC. Of note, the recently reported size analysis of plasma EBV DNA in patients with NPC has highlighted size as an important analytical parameter of ctDNA and demonstrated clinical value in improving the diagnostic performance of an EBV DNA‐based NPC screening test. Such insights into ctDNA analysis (including size profiling) may help its full potential in cancer diagnostics for other types of cancer to be realised. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.